Hartford Financial Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hartford Financial Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6K	Hold	28	–	–	﹤0.01%	333
2026 Q1	$1.58K	Hold	28	–	–	﹤0.01%	328
2025 Q4	$1.67K	Hold	28	–	–	﹤0.01%	320
2025 Q3	$1.52K	Hold	28	–	–	﹤0.01%	322
2025 Q2	$1.54K	Hold	28	–	–	﹤0.01%	328
2025 Q1	$1.98K	Hold	28	–	–	﹤0.01%	337
2024 Q4	$1.84K	Hold	28	–	–	﹤0.01%	361
2024 Q3	$1.97K	Hold	28	–	–	﹤0.01%	365
2024 Q2	$2.31K	Hold	28	–	–	﹤0.01%	356
2024 Q1	$2.45K	Hold	28	–	–	﹤0.01%	357
2023 Q4	$2.7K	Hold	28	–	–	﹤0.01%	362
2023 Q3	$2.48K	Buy	28 +10	+56%	+$890	﹤0.01%	360
2023 Q2	$1.56K	Hold	18	–	–	﹤0.01%	354
2023 Q1	$1.75K	Buy	+18	New	+$1.87K	﹤0.01%	353
2017 Q4	–	Sell	-610	Closed	-$56K	–	343
2017 Q3	$56K	Hold	610	–	–	0.03%	184
2017 Q2	$55K	Hold	610	–	–	0.02%	186
2017 Q1	$53K	Buy	+610	New	+$54.3K	0.03%	182

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Hartford Financial Management's BMRN Position: Q2 2026 in Review

Hartford Financial Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 28 shares worth $1.6K. The position accounts for ﹤0.01% of the portfolio, ranked #333.

Hartford Financial Management first reported a position in BMRN in Q1 2017 and has held it in 17 quarters since. The position peaked at $56K in Q3 2017. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Hartford Financial Management held 28 shares of BioMarin Pharmaceuticals worth $1.6K as of Q2 2026.
Hartford Financial Management left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Hartford Financial Management's portfolio in Q2 2026, its #333 holding.
Hartford Financial Management first reported a position in BioMarin Pharmaceuticals in Q1 2017 and has held it in 17 quarters since.
Hartford Financial Management's BioMarin Pharmaceuticals position peaked at $56K in Q3 2017.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Hartford Financial Management's 13F filing for Q2 2026, filed 24 Jul 2026.